Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug;11(4):583-585.
doi: 10.21037/hbsn-22-31.

Neoadjuvant therapy for resectable pancreatic cancers

Yosuke Inoue  1 , Hiromichi Ito  1 , Yu Takahashi  1
Affiliations
Editorial

Neoadjuvant therapy for resectable pancreatic cancers

Yosuke Inoue et al. Hepatobiliary Surg Nutr. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-31/coif). The authors have no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014;155:977-88. 10.1016/j.surg.2014.02.001 - DOI - PubMed
    1. Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013;20:590-600. 10.1007/s00534-013-0616-0 - DOI - PubMed
    1. Oba A, Inoue Y, Ono Y, et al. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbecks Arch Surg 2020;405:35-41. 10.1007/s00423-019-01846-2 - DOI - PubMed
    1. Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci 2021;28:143-55. 10.1002/jhbp.844 - DOI - PubMed
    1. Motoi F, Satoi S, Honda G, et al. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. 10.1007/s00535-018-1506-7 - DOI - PubMed